- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07759882
Screening & TReatment fOr Perinatal WomeN With PTSD in Substance Use Care SettinGs in Arkansas (STRONG Moms) (STRONG Moms)
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The primary objective is to evaluate the feasibility and acceptability of implementing a brief, telehealth-delivered behavioral intervention for PTSD among pregnant and postpartum individuals with a history of substance misuse. Secondary objectives include estimating the prevalence of probable PTSD in perinatal substance use treatment settings, assessing participant interest in receiving PTSD treatment while engaged in substance use care, and examining preliminary changes in PTSD and depressive symptoms following treatment.
The study consists of two sequential components. First, pregnant and postpartum individuals receiving services for problematic substance misuse in Arkansas will be screened for PTSD symptoms using the Primary Care PTSD Screen for DSM-5 (PC-PTSD-5). Screening will be conducted across multiple treatment and care settings, including inpatient and outpatient programs, to estimate the prevalence of probable PTSD and characterize willingness to participate in trauma-focused treatment during the perinatal period.
Second, individuals who meet eligibility criteria for PTSD treatment will participate in a mixed-methods, single-arm pre-post pilot evaluation of Written Exposure Therapy (WET), a brief evidence-based behavioral intervention for PTSD delivered via telehealth. Approximately 20 pregnant and postpartum participants with PTSD will receive the intervention. Feasibility will be assessed through measures such as recruitment, enrollment, retention, intervention completion, and assessment completion. Acceptability will be evaluated using participant-reported satisfaction and qualitative interviews exploring experiences with treatment delivery, barriers and facilitators to participation, and recommendations for implementation. Clinical assessments conducted before and after treatment will provide preliminary estimates of changes in PTSD symptoms and depressive symptoms.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Mollee K. Steely Smith K Assistant Professor, PhD
- Telefonnummer: 501-526-8174
- E-post: mksteelysmith@uams.edu
Studer Kontakt Backup
- Navn: Chelsey E Bull, PhD
- E-post: cebull@uams.edu
Studiesteder
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72205
- University of Arkansas for Medical Sciences
-
Ta kontakt med:
- Mollee K Steely Smith, PhD
- Telefonnummer: 501-526-8174
- E-post: mksteelysmith@uams.edu
-
Ta kontakt med:
- Chelsey E Bull, PhD
- E-post: cebull@uams.edu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Able to write, understand, and speak English
- Able to give informed consent
- Currently pregnant or postpartum (≤ 6 months after childbirth)
- History of substance misuse
- Receiving services for substance-use related problems
- Have a history of traumatic event exposure
- Endorse clinically significant PTSD symptoms (score ≥ 3 on the Primary Care PTSD Screen for DSM-5; PC-PTSD-5)
Exclusion Criteria:
- Unwilling to provide consent
- No history of Criterion A trauma exposure or clinically significant PTSD symptoms
- No history of substance misuse or currently receiving services for a substance-use related problem
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Single Arm Intervention
All participants will receive Written Exposure Therapy (WET)
|
Written Exposure Therapy (WET) is a brief, evidence-based therapy for PTSD.
Clients receive 5 weekly sessions where they write about a traumatic experience in a safe, structured way for approximately 50 minutes followed by a brief check-in with their therapist.
This process helps individuals make sense of the event, reduce emotional distress, and decrease PTSD symptoms over time.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Acceptability
Tidsramme: From baseline to end of treatment at 5 weeks
|
Acceptability will be evaluated using the Client Satisfaction Questionnaire (CSQ-8), an 8-item participant-reported satisfaction measure rated on a 4-point Likert scale.
Total scores ranging from 8-32, with higher scores indicating greater satisfaction with the therapy.
|
From baseline to end of treatment at 5 weeks
|
|
Acceptability
Tidsramme: From baseline to end of treatment at 5 weeks
|
Acceptability will also be evaluated using the Acceptability of Intervention (AIM), which is a 4-item self-reported questionnaire on a 5-point Likert scale assessing acceptability of the intervention.
Scores are summed and higher scores indicate greater acceptability.
|
From baseline to end of treatment at 5 weeks
|
|
Feasibility of Recruitment
Tidsramme: From enrollment to end of treatment at 5 weeks
|
Feasibility of recruitment will be assessed by the number of individuals who initiated WET versus the total number of individuals enrolled in the study.
|
From enrollment to end of treatment at 5 weeks
|
|
Therapy Adherence
Tidsramme: From enrollment to end of treatment at 5 weeks
|
Therapy adherence will be assessed by WET session attendance and completion.
We will measure therapy adherence by the number of individuals who complete ≥ 4 sessions versus the total number of individuals who received ≤ 3 sessions.
|
From enrollment to end of treatment at 5 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
PTSD Symptoms
Tidsramme: From enrollment to the end of treatment at 5 weeks
|
Changes in PTSD symptoms will be assessed using the PTSD Checklist for DSM-5 (PCL-5), a 20-item self-report questionnaire on symptoms of PTSD.
Scores range from 0-80, with higher scores indicating a greater PTSD symptom severity.
|
From enrollment to the end of treatment at 5 weeks
|
|
Depression Symptoms
Tidsramme: From enrollment to end of treatment at 5 weeks
|
Depression symptoms will be assessed using the Personal History Questionnaire (PHQ-9), a 9-item questionnaire used to assess depression symptoms over the past 2 weeks.
Total scores range from 0-27, with higher scores indicating greater severity of depression symptoms
|
From enrollment to end of treatment at 5 weeks
|
|
Substance Use Severity
Tidsramme: From enrollment to end of treatment at 5 weeks
|
The DSM-5 Drug Use Disorder (DUD) and Alcohol Use Disorder (AUD) Symptom Checklist is a self-report measure to assess the presence of diagnostic criteria for drug use disorders.
This measure evaluates the 11 DSM-5 criteria for drug use disorders, including impaired control, social impairment, risky use, and pharmacologic indicators (tolerance/withdrawal).
Endorsement of a greater number of criteria indicates greater severity and can be categorized as mild, moderate, or severe.
|
From enrollment to end of treatment at 5 weeks
|
|
Pre/Postnatal Depression Symptoms
Tidsramme: From enrollment to the end of treatment at 5 weeks
|
The Edinburgh Postnatal Depression Scale (EPDS), a 10-item self-report questionnaire to assess depressive symptoms experiences during the previous 7 days in pregnant and postpartum individuals, will also be used to assess perinatal postpartum depression.
Total scores range from 0-30, with higher scores indicating greater severity of depressive symptoms.
|
From enrollment to the end of treatment at 5 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Mollee K Steely Smith, PhD, University of Arkansas
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 300210
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .